1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > EpiCast Report: Cushing’s Syndrome - Epidemiology Forecast to 2023

EpiCast Report: Cushing’s Syndrome - Epidemiology Forecast to 2023

Summary

Cushing’s syndrome (CS) is a rare disorder caused by prolonged exposure to excess amounts of circulating free glucocorticoids, such as cortisol. Cortisol is a hormone produced by the adrenal glands that has many functions in the body, such as anti-inflammatory action, antiallergic action, antianabolic action, and amino acid catabolic action. CS is associated with increased mortality caused by complications due to excess cortisol.

GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of CS in the 6MM, from 32,634 diagnosed prevalent cases in 2013 to 34,573 diagnosed prevalent cases in 2023, at an annual growth rate of 0.59% in the forecast period. In 2023, the US will have the highest number of diagnosed prevalent cases of CS, with 17,162 diagnosed prevalent cases.

For this analysis, GlobalData epidemiologists used data available from the Orphanet database to construct the 10-year epidemiological forecast for the diagnosed prevalent cases of Cushing’s disease, ectopic ACTH CS, adrenal adenoma CS, and adrenal carcinoma CS in the 6MM. The forecast provides the age- and sex-specific diagnosed prevalent cases of CS subtypes in the six markets, providing a comprehensive view of CS. In addition, this analysis provides detailed, clinically relevant segmentations for Cushing’s disease in order to improve the management of the disease.

Scope

- The Cushing’s syndrome (CS) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for CS in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). The report also includes a 10-year epidemiological forecast for the diagnosed prevalent cases of CS, Cushing’s disease, ectopic- adrenocorticotropic hormone (ACTH) CS, adrenal adenoma CS, and adrenal carcinoma CS segmented by age (18 to =85 years) and sex in these markets.
- The CS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global CS market.
- Quantify patient populations in the global CS market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for CS therapeutics in each of the markets covered.

Table Of Contents

EpiCast Report: Cushing’s Syndrome - Epidemiology Forecast to 2023
1 Table of Contents
2 Introduction 7
2.1 Catalyst 7
2.2 Related Reports 8
2.3 Upcoming Related Reports 8
3 Epidemiology 9
3.1 Disease Background 9
3.2 Risk Factors and Comorbidities 10
3.3 Global Trends 12
3.3.1 US 12
3.3.2 5EU 12
3.4 Forecast Methodology 12
3.4.1 Sources Used 15
3.4.2 Sources Not Used 17
3.4.3 Forecast Assumptions and Methods - Prevalent Cases 18
3.4.4 Forecast Assumptions and Methods - Immediate TSS Outcomes 19
3.5 Epidemiological Forecast for Cushing's Syndrome (2013-2023) 20
3.5.1 Cushing's Syndrome 20
3.5.2 Cushing's Disease 25
3.5.3 Ectopic Adrenocorticotropic Hormone Cushing's Syndrome 32
3.5.4 Adrenal Adenoma Cushing's Syndrome 37
3.5.5 Adrenal Carcinoma Cushing's Syndrome 43
3.5.6 Age-Standardized Diagnosed Prevalence Rates 49
3.5.7 Immediate Transsphenoidal Adenomectomy Surgery Outcomes 51
3.6 Discussion 52
3.6.1 Epidemiological Forecast Insight 52
3.6.2 Limitations of the Analysis 53
3.6.3 Strengths of the Analysis 54
4 Appendix 55
4.1 Bibliography 55
4.2 About the Authors 58
4.2.1 Epidemiologists 58
4.2.2 Reviewers 58
4.2.3 Global Director of Therapy Analysis and Epidemiology 60
4.2.4 Global Head of Healthcare 60
4.3 About GlobalData 61
4.4 About EpiCast 61
4.5 Disclaimer 61

1.1 List of Tables

Table 1: Risk Factors for Cushing's Syndrome 11
Table 2: 6MM, Sources of CS Prevalence Data 13
Table 3: 6MM, Diagnosed Prevalent Cases of CS, Ages ?18 Years, Both Sexes, N, Selected Years 2013-2023 20
Table 4: 6MM, Age-Specific Diagnosed Prevalent Cases of CS, Both Sexes, N (Row %), 2013 22
Table 5: 6MM, Sex-Specific Diagnosed Prevalent Cases of CS, Ages ?18 Years, N (Row %), 2013 24
Table 6: 6MM, Diagnosed Prevalent Cases of Cushing's Disease, Ages ?18 Years, Both Sexes, N, Selected Years 2013-2023 26
Table 7: 6MM, Age-Specific Diagnosed Prevalent Cases of Cushing's Disease, Both Sexes, N (Row %), 2013 28
Table 8: 6MM, Sex-Specific Diagnosed Prevalent Cases of Cushing's Disease, Ages ?18 Years, N (Row %), 2013 30
Table 9: 6MM, Diagnosed Prevalent Cases of Ectopic ACTH CS, Ages ?18 Years, Both Sexes, N, Selected Years 2013-2023 32
Table 10: 6MM, Age-Specific Diagnosed Prevalent Cases of Ectopic ACTH CS, Both Sexes, N (Row %), 2013 34
Table 11: 6MM, Sex-Specific Diagnosed Prevalent Cases of Ectopic ACTH CS, Ages ?18 Years, N (Row %), 2013 36
Table 12: 6MM, Diagnosed Prevalent Cases of Adrenal Adenoma CS, Ages ?18 Years, Both Sexes, N, Selected Years 2013-2023 38
Table 13: 6MM, Age-Specific Diagnosed Prevalent Cases of Adrenal Adenoma CS, Both Sexes, N (Row %), 2013 40
Table 14: 6MM, Sex-Specific Diagnosed Prevalent Cases of Adrenal Adenoma CS, Ages ?18 Years, N (Row %), 2013 42
Table 15: 6MM, Diagnosed Prevalent Cases of Adrenal Carcinoma CS, Ages ?18 Years, Both Sexes, N, Selected Years 2013-2023 44
Table 16: 6MM, Age-Specific Diagnosed Prevalent Cases of Adrenal Carcinoma CS, Both Sexes, N (Row %), 2013 46
Table 17: 6MM, Sex-Specific Diagnosed Prevalent Cases of Adrenal Carcinoma CS, Ages ?18 Years, N (Row %), 2013 48
Table 18: 6MM, Immediate TSS Outcomes, Both Sexes, N, 2013 52

1.2 List of Figures

Figure 1: 6MM, Diagnosed Prevalent Cases of CS, Ages ?18 Years, Both Sexes, N, 2013-2023 21
Figure 2: 6MM, Age-Specific Diagnosed Prevalent Cases of CS, Both Sexes, N, 2013 23
Figure 3: 6MM, Sex-Specific Diagnosed Prevalent Cases of CS, Ages ?18 Years, N, 2013 25
Figure 4: 6MM, Diagnosed Prevalent Cases of Cushing's Disease, Ages ?18 Years, Both Sexes, N, 2013-2023 27
Figure 5: 6MM, Age-Specific Diagnosed Prevalent Cases of Cushing's Disease, Both Sexes, N, 2013 29
Figure 6: 6MM, Sex-Specific Diagnosed Prevalent Cases of Cushing's Disease, Ages ?18 Years, N, 2013 31
Figure 7: 6MM, Diagnosed Prevalent Cases of Ectopic ACTH CS, Ages ?18 Years, Both Sexes, N, 2013-2023 33
Figure 8: 6MM, Age-Specific Diagnosed Prevalent Cases of Ectopic ACTH CS, Both Sexes, N, 2013 35
Figure 9: 6MM, Sex-Specific Diagnosed Prevalent Cases of Ectopic ACTH CS, Ages ?18 Years, N, 2013 37
Figure 10: 6MM, Diagnosed Prevalent Cases of Adrenal Adenoma CS, Ages ?18 Years, Both Sexes, N, 2013-2023 39
Figure 11: 6MM, Age-Specific Diagnosed Prevalent Cases of Adrenal Adenoma CS, Both Sexes, N, 2013 41
Figure 12: 6MM, Sex-Specific Diagnosed Prevalent Cases of Adrenal Adenoma CS, Ages ?18 Years, N, 2013 43
Figure 13: 6MM, Diagnosed Prevalent Cases of Adrenal Carcinoma CS, Ages ?18 Years, Both Sexes, N, 2013-2023 45
Figure 14: 6MM, Age-Specific Diagnosed Prevalent Cases of Adrenal Carcinoma CS, Both Sexes, N, 2013 47
Figure 15: 6MM, Sex-Specific Diagnosed Prevalent Cases of Adrenal Carcinoma CS, Ages ?18 Years, N, 2013 49
Figure 16: 6MM, Age-Standardized Diagnosed Prevalence of CS (%), Ages ?18 Years, 2013 50
Figure 17: 6MM, Age-Standardized Diagnosed Prevalence of Cushing's Disease (%), Ages ?18 Years, 2013 51

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025 Summary Human Epidermal growth factor Receptor type 2 (HER2-) breast cancer is the second ...

Epiomic Epidemiology Series: Liver Cancer Forecast in 18 Major Markets 2017-2027

Epiomic Epidemiology Series: Liver Cancer Forecast in 18 Major Markets 2017-2027

  • $ 5112
  • Industry report
  • February 2017
  • by Black Swan Analysis Ltd

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Liver Cancer in 18 Major Markets Liver Cancer, also known as hepatic cancer or primary liver cancer, is a cancer which starts in the ...

Epiomic Epidemiology Series: Non-Hodgkin Lymphoma Forecast in 18 Major Markets 2017-2027

Epiomic Epidemiology Series: Non-Hodgkin Lymphoma Forecast in 18 Major Markets 2017-2027

  • $ 5112
  • Industry report
  • February 2017
  • by Black Swan Analysis Ltd

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Non-Hodgkin Lymphoma in 18 Major Markets Non-Hodgkin Lymphomas (NHL) are a diverse group of blood cancers that develop from lymphocytes ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.